A clinical study with the VibroSense Meter concludes that the company's instruments can be used instead of the "Gold standard" for early detection of nerve damage in feet caused by type 1 diabetes
Doctor Eero Lindholm at Skåne University Hospital presented unique results from clinical study of Diabetic Peripheral Neuropathy (DPN) of feet in patients with type 1 diabetes. The results were presented at the world's second largest diabetes congress - EASD in Barcelona on September 17, 2019. The conclusion was that VibroSense technology and instruments can be used instead of Nerve Conduction Studies (NCS), for early diagnosis of nerve damage in feet caused by type 1 diabetes.
Dr. Lindholm presented his results at a poster presentation. One of his conclusions was that he could see a significant correlation between VibroSense technology Multi Frequency Vibrometry and Nerve Conduction Studies which are the "Gold Standard" at the diagnosis of nerve injury in feet caused by type 1 diabetes. The study was made on 50 patients and the results showed an overall strong correlation with nerve conduction studies on several nerve trunks in the foot. Strongest correlation, -0.81, was obtained at 125 Hz under the big toe against the nerve conduction amplitude (SNAP) on the Suralis nerve in the foot. A correlation of +1 or -1 corresponds to equivalent results.
The poster can be downloaded at the following link- NCS-Poster-EASD
- This publication is an important piece of the puzzle for the successful launch of Multi Frequency Vibrometry and our new instrument VibroSense Meter II. We are heading to show that our technology can replace the “Gold Standard” with an instrument we offer to Primary and Specialist care. Dr. Lindholm's results mean that the VibroSense Meter II would be a significantly faster, painless and much cheaper alternative, compared to current nerve conduction examinations. Our next goal is to show that Multi Frequency Vibrometry is a superior and more sensitive method than the current "Gold Standard", says Toni Speidel, CEO of VibroSense Dynamics AB.
Toni Speidel, VD VibroSense Dynamics AB,
Phone: +46 40 88 026
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (public) sells and develops efficient systems to support early detection and diagnosis of sensory neuropathy, i.e. disease of large nerve fibres and nerve trunks in e.g. legs and arms. Our vision is that the VibroSense Meter shall be the Gold Standard instrument for neurological examinations to assess sensory neuropathy and help to improve life conditions for patients having a risk of getting nerve injuries.